The T2DM group received a combination treatment of metformin and SBU for eight weeks (T2DM+met+SBU), significantly increasing the mRNA GLUT4 in the muscle of the T2DM+met+SBU group compared with the other group (Figure 4m). This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.